SCHEMBL769090

SCHEMBL769090

COc1ccc(CNc2ccc3c(c2)ncn3-c2ccccc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.77
FLT3 P36888 2/20 0.77
ALDH1A1 P00352 11/20 0.75
MAPT P10636 10/20 0.75
KDM4E B2RXH2 10/20 0.75
HPGD P15428 9/20 0.75
TDP1 Q9NUW8 4/20 0.75
L3MBTL1 Q9Y468 3/20 0.75
GAA P10253 4/20 0.72
RAB9A P51151 7/20 0.71
SMN1; SMN2 Q16637 5/20 0.71
HTT P42858 3/20 0.71
MAPK1 P28482 2/20 0.71
MEN1 O00255 1/20 0.71
KMT2A Q03164 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71
NPC1 O15118 7/20 0.67
LMNA P02545 4/20 0.67
ALOX15 P16050 1/20 0.67
TSHR P16473 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770038 0.94 MAPT (0.72) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL770130 0.94 MAPT (0.70) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769341 0.94 MAPT (0.70) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769148 0.94 MAPT (0.70) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769285 0.94 MAPT (0.70) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL770202 0.92 MAPT (0.67) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769636 0.90 MAPT (0.65) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769649 0.90 KDM4E (0.67) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769865 0.90 MAPT (0.69) KITFLT3ALDH1A1MAPTKDM4E
SCHEMBL769828 0.90 KDM4E (0.67) KITFLT3ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US claimed
EP-1988776-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC (US) 2012-08-08 EP claimed
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2011-07-14 US claimed
US-7977365-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-07-12 US claimed
EP-2291184-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-09 EP claimed
US-7872037-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-01-18 US claimed
WO-2010036399-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2010-04-01 WO claimed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US claimed
EP-1988776-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2008-11-12 EP claimed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US claimed
WO-2007103111-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2007-09-13 WO claimed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection GK, GALK1, KLK7 KIT 3719/4885FLT3 4523/4885ALDH1A1 4463/4885
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection GK, GALK1, GZMB KIT 3932/4885FLT3 4553/4885ALDH1A1 4481/4885
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION GK, MAVS, ZC3HAV1 KIT 3957/4885FLT3 4618/4885ALDH1A1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.